Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 8/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708108 | 1.00 | SIGMAR1 (0.38) | SIGMAR1POLBSMN1; SMN2CXCR4MEN1 | |
| SCHEMBL7710694 | 1.00 | SIGMAR1 (0.38) | SIGMAR1POLBSMN1; SMN2CXCR4MEN1 | |
| SCHEMBL7708139 | 0.86 | — | — | |
| SCHEMBL7708147 | 0.86 | — | — | |
| SCHEMBL7707623 | 0.77 | — | — | |
| SCHEMBL7707620 | 0.77 | — | — | |
| SCHEMBL7708132 | 0.77 | — | — | |
| SCHEMBL175418 | 0.76 | POLB (0.35) | SIGMAR1POLBSMN1; SMN2CXCR4MEN1 | |
| SCHEMBL7710736 | 0.76 | SMN1; SMN2 (0.35) | SIGMAR1POLBSMN1; SMN2CXCR4MEN1 | |
| SCHEMBL1481327 | 0.76 | POLB (0.35) | SIGMAR1POLBSMN1; SMN2CXCR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013824-B1 | CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | ALZPROTECT (FR) | 2018-05-16 | — | — | EP | disclosed |
| US-9714245-B2 | Carboline compounds usable in the treatment of neurodegenerative diseases | ALZPROTECT (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-06-02 | — | — | US | disclosed |
| EP-3013824-A1 | CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Alzprotect (FR) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014207241-A1 | NEW Na-SUBSTITUTED CARBOLINE COMPOUNDS USABLE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ALZPROTECT (FR) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207240-A1 | CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | ALZPROTECT (FR) | 2014-12-31 | — | — | WO | disclosed |
| EP-1171133-B1 | R-HYDROXYNEFAZODONE | SEPRACOR INC (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1358171-A2 | NOVEL UREA DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | Aventis Pharma S.A. (FR) | 2003-11-05 | — | — | EP | disclosed |
| US-6465470-B2 | TREATMENT FOR DEPRESSION WHICH DOES NOT GIVE RISE TO THE ADVERSE EFFECTS ASSOCIATED WITH NEFAZODONE; ALSO USEFUL IN THE TREATMENT OF MIGRAINE HEADACHES, PANIC DISORDERS, POST TRAUMATIC STRESS DISORDER AND SLEEP DISORDERS. | SEPRACOR INC. | 2002-10-15 | — | — | US | disclosed |
| US-6465469-B1 | S-hydroxynefazodone | SEPRACOR INC. | 2002-10-15 | — | — | US | disclosed |
| WO-2002059102-A2 | UREA DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE | AVENTIS PHARMA S.A. (FR) | 2002-08-01 | — | — | WO | disclosed |
| US-6384037-B1 | TREATMENT OF PSYCHIATRIC ILLNESS, ANTIDEPRESSANTS, SLEEP DISORDERS AND ANALGESICS | SEPRACOR INC. | 2002-05-07 | — | — | US | disclosed |
| US-20020052382-A1 | R-hydroxynefazodone | SEPRACOR INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1189616-A2 | S-HYDROXYNEFAZODONE | Sepracor Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6359174-B1 | REACTING ALLYL REACTANT WITH ACID CHLORIDE IN PRESENCE OF LEWIS ACID CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-03-19 | — | — | US | disclosed |
| EP-1171133-A2 | R-HYDROXYNEFAZODONE | Sepracor Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061129-A2 | S-HYDROXYNEFAZODONE | SEPRACOR INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000061128-A2 | R-HYDROXYNEFAZODONE | SEPRACOR INC. (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052382-A1 | R-hydroxynefazodone | OPRD1, HTR4, HTR3E | SIGMAR1 106/4885POLB 2071/4885SMN1; SMN2 2145/4885 |
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | SIGMAR1 923/4885POLB 1835/4885SMN1; SMN2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.